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Triglyceride-rich lipoproteins (TRLs) undergo lipol-
ysis by lipoprotein lipase (LPL), an enzyme that is
transported to the capillary lumen by an endothelial
cell protein, GPIHBP1. For LPL-mediated lipolysis
to occur, TRLs must bind to the lumen of capillaries.
This process is often assumed to involve heparan
sulfate proteoglycans (HSPGs), but we sus-
pected that TRL margination might instead require
GPIHBP1. Indeed, TRLs marginate along the heart
capillaries of wild-type but not Gpihbp1–/– mice, as
judged by fluorescence microscopy, quantitative
assays with infrared-dye-labeled lipoproteins, and
EM tomography. Both cell-culture and in vivo studies
showed that TRL margination depends on LPL
bound to GPIHBP1. Notably, the expression of LPL
by endothelial cells in Gpihbp1–/– mice did not
restore defective TRL margination, implying that
the binding of LPL to HSPGs is ineffective in pro-
moting TRL margination. Our studies show that
GPIHBP1-bound LPL is the main determinant of
TRL margination.
INTRODUCTION
The triglycerides within the core of triglyceride-rich lipoproteins
(TRLs; chylomicrons and VLDL) undergo hydrolysis by lipopro-
tein lipase (LPL) in the capillary lumen, mainly in heart, skeletal
muscle, and adipose tissue (Brunzell and Deeb, 2001; Havel
and Kane, 2001). LPL is synthesized by parenchymal cells,
but its site of action is within the capillary lumen. The mecha-Cnism by which LPL reaches the capillary lumen was recently
solved. LPL in the interstitial spaces is bound by GPIHBP1,
a GPI-anchored protein of endothelial cells, and then trans-
ported across the cells to the capillary lumen (Davies et al.,
2012; Davies et al., 2010). In the setting of GPIHBP1 defi-
ciency, LPL accumulates in the interstitial spaces and cannot
reach the capillary lumen, resulting in severe hypertriglyce-
ridemia (chylomicronemia) (Beigneux et al., 2007; Davies
et al., 2010) and reduced delivery of lipid nutrients to paren-
chymal cells (Weinstein et al., 2012). GPIHBP1 is not
expressed in endothelial cells of larger blood vessels (e.g.,
arteries, veins), nor is it expressed in capillaries of the brain
(Beigneux et al., 2007; Davies et al., 2010), an organ that
primarily uses glucose for fuel.
For lipolysis to proceed, TRLs in the bloodstream need to
stop at the luminal face of capillaries. The partitioning of large
TRLs along the capillary endothelium has been aptly called
‘‘margination’’ (Stalenhoef et al., 1986). The molecule(s) on
endothelial cells responsible for capturing TRLs in the blood-
stream has remained unclear. One possibility, proposed in
several reviews (Cryer, 1989; Goldberg, 1996), is that TRLs
bind to the luminal surface of capillaries by interacting with
heparan sulfate proteoglycans (HSPGs) lining capillary endo-
thelial cells. This model seems plausible, given that several
apolipoproteins on TRLs contain positively charged heparin-
binding domains (e.g., apo-B, apo-AV, apo-E) and are known
to bind to negatively charged HSPGs (Brown and Goldstein,
1986; Cardin et al., 1984, 1986; Lookene et al., 2005; Mullick
et al., 2002). According to this model, lipolysis of TRLs pro-
ceeds because of the proximity of HSPG-bound TRLs to LPL
in the capillary lumen. In a variation of this model, HSPG-
bound LPL contributes to TRL binding. LPL contains heparin-
binding domains that interact with HSPGs and also contains
lipid-binding sequences that bind (at least in biochemical as-
says) TRLs and triglyceride-rich emulsion particles (Lookeneell Metabolism 19, 849–860, May 6, 2014 ª2014 Elsevier Inc. 849
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capillary HSPGs and TRL particles (Merkel et al., 1998). There
is indirect support for this model. When LPL is added to iso-
lated and perfused arteries (where the LPL is presumably
attached to HSPGs), there is increased binding of fluorescently
labeled TRLs to the arterial wall (Mullick et al., 2002). However,
direct investigations of TRL margination in capillaries have
lagged behind, at least in part because of the absence of
experimental approaches to visualize and quantify TRL margin-
ation within the microvasculature.
In this study, we sought to definemechanisms for TRLmargin-
ation in capillaries. We developed techniques for imaging and
quantifying TRL margination and examined the possibility that
GPIHBP1 might be crucial for this process. We found that
GPIHBP1—and more specifically GPIHBP1-bound LPL—is the
main determinant of TRL margination in the microvascular
circulation.
RESULTS
Binding of Triglyceride-Rich Lipoproteins to Small Blood
Vessels in the Heart in Wild-Type Mice but Not in
Gpihbp1 Knockout Mice
We hypothesized that TRL margination might require GPIHBP1
and/or GPIHBP1-bound LPL. We began by testing whether
TRLs would stop along capillaries in Gpihbp1–/– mice. We
labeled TRLs (d < 1.006 g/ml lipoproteins from Gpihbp1–/–
mice) with Alexa 555 and injected them intravenously (along
with FITC-labeled tomato lectin) into wild-type and Gpihbp1–/–
mice. After 30 s, the mice were perfused with PBS to remove un-
bound lipoproteins and fixed in situ, and tissue samples were
prepared for microscopy. As expected, the tomato lectin bound
to endothelial cells (both in capillaries and larger blood vessels).
However, the TRLs bound only to heart capillaries in wild-type
mice and did not bind to larger blood vessels (Figure 1A, arrow-
heads) or to capillaries in the brain (see Figure S1A available
online) (two sites where GPIHBP1 expression is absent)
(Beigneux et al., 2007; Davies et al., 2010). TRL margination
was nearly absent in heart capillaries of Gpihbp1–/– mice (Fig-
ure 1A). The TRLs in wild-type mice colocalized with GPIHBP1
and LPL (Figure S1B) and were located along the luminal side
of capillary endothelial cells (Figure 1B). Transmission electron
microscopy (EM) demonstrated binding of TRLs to the luminal
face of heart capillaries in wild-type mice (Figure 1C), but there
was no TRL binding to heart capillaries of Gpihbp1–/– mice (Fig-
ure 1C). The identity of injected TRL particles along the surface of
capillaries was confirmed by nanosecondary ion mass spec-
trometry (nanoSIMS) imaging (Moore et al., 2012). This tech-
nique makes it possible to visualize stable isotopes (e.g., 13C)
in biological samples with 50 nm lateral resolution. For these
studies, 13C-labeled TRLs from a Gpihbp1–/– mouse were
injected intravenously into a wild-type and Gpihbp1–/– mouse.
After 8 min, the hearts were perfused extensively and fixed,
and tissue sections were analyzed by nanoSIMS imaging. 13C
enrichment in the nanoSIMS images often coincided with lipo-
proteins at the luminal surface of capillaries in wild-type mice
(visualized by low-voltage back-scattered EM from the same
section). No lipoproteins were detected in capillaries of
Gpihbp1–/– mice (Figure S1C).850 Cell Metabolism 19, 849–860, May 6, 2014 ª2014 Elsevier Inc.TRLsBind to theOpenSpaces in betweenPatches of the
Glycocalyx
The luminal surface of vascular endothelial cells is covered by a
glycocalyx that is rich in glycoproteins and proteoglycans (Arkill
et al., 2012; Reitsma et al., 2007). To characterize the binding of
TRLs in relation to the endothelial cell glycocalyx, unlabeled
TRLs were injected into a wild-type mouse, perfused with PBS
to remove unbound lipoproteins, and stained with Alcian blue
to visualize the glycocalyx (Reitsma et al., 2007). The glycocalyx
in large blood vessels (e.g., venules) of the heart appears as a
continuous dense ‘‘forest’’ extending200 nmabove the luminal
surface (Figure 2). In contrast, the glycocalyx in heart capillaries
is patchy, with ‘‘tufts’’ of glycocalyx (75-nm tall) interspersed
between open spaces where the plasma membrane is exposed
(Figure 2). A patchy appearance of the glycocalyx has also been
observed in rat peritubular capillaries (Arkill et al., 2012). TRLs
bound to the gaps between tufts of glycocalyx (Figure 2; also
see Movie S1 and Movie S2).
Identification of ‘‘Nanovilli’’ by Dual-Axis EM
Tomography and Their Association with TRLs
We also examined the margination of TRLs by dual-axis elec-
tron tomography, making it possible to visualize TRLs in
250 nm-thick sections (Mastronarde, 1997). Consistent with
the routine transmission EM studies, multiple TRLs were found
on the endothelial cell surface in wild-type mice, but not in
Gpihbp1–/– mice (Figure S2). Many TRL particles appeared to
be attached to thin plasma membrane projections located at
the luminal surface (Figures 3A–3C and S2). The projections
on the luminal surface were 6.6 ± 0.3 nm (n = 21) in diameter
and ranged in height from 100 to 200 nm. The same membrane
projections were also found within caveolar-like invaginations
of endothelial cells (Figures 3D and 3E), in transcytotic vesicles
or channels (Figures 3D–3F), and on the plasma membrane at
the basolateral face of cells (Figure 3E). These structures were
also found in heart capillary endothelial cells of Gpihbp1–/–
mice, but not in adjacent myocytes (Figure S2). EM did not
reveal any cytoplasm or structural elements (e.g., actin
filaments) within the membrane projections, but they had the
hallmark ‘‘railroad-track morphology’’ of lipid bilayers (Robert-
son, 1960) (Figure 3F). These structures, which we have called
‘‘nanovilli,’’ appear as ‘‘sticks’’ on individual EM micrographs.
However, when examined stepwise along the z axis, an individ-
ual nanovillus often appears in many micrographs—as many as
15–20 (see Movie S4, Movie S5, and Movie S6). This suggests
that the membrane projections are actually lipid bilayer
‘‘planes’’ (6 nm thick, 30–40 nm long, and 100–200 nm tall).
These structures had not been noted previously, almost
certainly because clear visualization of these structures re-
quires EM tomography (they are infrequent and subtle by
routine transmission EM). To determine whether nanovilli might
contain GPIHBP1, we performed immunogold labeling with a
GPIHBP1-specific rat monoclonal antibody. In preliminary
studies, detection of GPIHBP1 was limited when primary or
secondary antibodies were conjugated to colloidal gold. We
therefore used unlabeled anti-GPIHBP1 antibodies along with
anti-rat Fab0 fragments conjugated to 1.4 nm gold beads.
Using 1.4 nm beads requires that tissue sections be treated
with silver enhancement solutions to produce particles large
Figure 1. Binding of Triglyceride-Rich Lipoproteins to Small Blood Vessels in the Heart
(A) FITC-labeled lectin and Alexa 555-labeled TRLs were mixed together and injected into a Gpihbp1+/+ and Gpihbp1–/– mouse. The lectin binds to endothelial
cells and is used to identify all blood vessels (green). TRLs (red) bound exclusively to small capillaries in the wild-type heart and were absent from larger blood
vessels (see arrowhead). DAPI was used to visualize nuclei (blue).
(B) High-magnification confocal fluorescence microscopy images showing TRL binding in the lumen of a capillary. A wild-type mouse was injected with Alexa
555-labeled TRLs (red), and after 30 s unbound lipoproteins were removed by perfusion. Heart sections were stained with antibodies against GPIHBP1 (green)
and CD31 (magenta), a marker of endothelial cells, and DAPI to visualize nuclei (blue).
(C) Transmission EM showing numerous TRLs along the luminal surface of capillaries in theGpihbp1+/+ heart but none in capillaries of theGpihbp1–/– heart. In the
wild-type heart capillary, there were a few lipoproteins that appeared separated from the endothelial cell surface (arrow). Scale bar, 200 nm.
(D) NanoSIMS analysis showing TRL binding to capillary endothelial cells in the heart. A wild-type mouse was injected with 13C-labeled TRLs and after 8 min was
perfused with PBS to remove unbound lipoproteins. Heart tissue sections were analyzed by nanoSIMS and back-scattered electron (BSE) imaging. The
13C-signal was normalized to the 12C signal. A 13C/12C signal in the natural abundance range appears blue, whereas an increased 13C/12C signal appears yellow-
red. Areas of 13C/12C enrichment corresponded to TRLs at the capillary lumen (detected by high-resolution BSE imaging on the same sections; arrows).
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silver-enhanced gold particles on capillary endothelial cells in
wild-type mice, but none in Gpihbp1–/– mice (Figure S2).
Most of the gold particles were located on the luminal surface,
especially within caveolae-like invaginations, but they were
also detected within intracellular vesicles and on the basolat-
eral surface. To determine if gold particles were also on nano-
villi, EM tomography was performed. Unfortunately, the silver
enhancement procedure interferes with the osmium and uranyl
acetate staining of membranes, including nanovilli. However,
linear ‘‘strings’’ of gold particles projecting into the capillary
lumen (and within endothelial cell vesicles) were often found
by EM (Figures 3G–3I).CQuantitative Measurement of TRL Margination In Vivo
To quantify TRLmargination, micewere injected with lipoproteins
that had been labeled with infrared (IR) dyes. In these studies,
wild-typeandGpihbp1–/–micewerepretreatedwith tetrahydrolip-
statin (THL) to prevent lipolysis. After 30 s, themicewere perfused
extensively, first with PBS and thenwith fixative. Next, frozen sec-
tions of mouse tissues were cut, and the level of each IR dye in
tissue sections was quantified with an IR scanner. In initial
studies, we compared the binding of IR800-dye-labeled TRLs
and IR680-dye-labeled cholesterol ester-rich mouse b-VLDL.
IR800-dye-labeled TRLs bound avidly to the heart, liver, and
brown adipose tissue (BAT) of wild-type mice, while TRL binding
in the brain was nearly undetectable (Figures 4A and 4B).ell Metabolism 19, 849–860, May 6, 2014 ª2014 Elsevier Inc. 851
Figure 2. Alcian Blue Staining and Dual-Axis Electron Microscopy Tomography of Hearts from Mice Showing TRL Binding in between
Patches of Glycocalyx
Unlabeled TRLs were injected into wild-type mice. After 30 s, the mice were perfused with PBS to remove unbound lipoproteins, followed immediately with
glutaraldehyde fixative containing Alcian blue to stain the glycocalyx. Embedded heart tissues were sectioned and examined by dual-axis electron tomography.
TRLs bind to gaps inbetween patches of glycocalyx. Higher-magnification images of the boxed areas are shown in the lower panels. Note the close apposition of
the TRLs with the endothelial cell plasma membrane. Scale bar, 800 nm. The complete tomogram can be viewed in Movie S1, Movie S2, and Movie S3.
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TRL Margination Depends on an LPL–GPIHBP1 ComplexIn Gpihbp1–/– mice, the binding of TRLs to the liver was similar to
that observed in wild-type mice, but the binding of TRLs to heart
and BAT was lower. IR680-dye-labeled b-VLDL bound avidly to
the liver, but binding to heart and adipose tissue was low in both
wild-type and Gpihbp1–/– mice (Figures 4C and 4D).
The binding of IR-dye TRLs to the heart was heparin sensitive
and was lower in Gpihbp1–/– mice than in wild-type mice when
normalized to tissue area or to endothelial cell content (Figures
S3A and S3B). Like TRLs isolated from the plasma ofGpihbp1–/–
mice, IR-dye-labeled human VLDL bound avidly to wild-type
mouse hearts, but binding to Gpihbp1–/– hearts was low (Fig-
ure S3C). In contrast, IR-dye-labeled HDL bound poorly to
wild-type mouse hearts but bound avidly to adrenal glands in
both wild-type and Gpihbp1–/– mice (Figure S3D). The binding
of TRLs to the heart was also examined with other IR dyes
(e.g., IR680, maleimide-IR800), but the results were the same:
the binding of TRLs to the heart depended on GPIHBP1 and
could be blocked with heparin.
The Reduced Binding of TRLs in Gpihbp1–/– Mouse
Hearts Is Not Due to High Plasma Triglyceride Levels
We considered the possibility that reduced binding of labeled
TRLs to heart capillaries in Gpihbp1–/– mice was somehow the
consequence of higher levels of TRLs in the plasma of those
mice. However, two lines of evidence showed that this was not
the case. The first involved studies with isolated, perfused
hearts. Hearts from Gpihbp1–/– mice were perfused extensively
with buffer (to remove all lipoproteins) and then with buffer con-
taining Alexa 555-labeled TRLs, Alexa647-labeled rat IgG, and
FITC-labeled lectin. After 5 min at 4C, hearts were perfused
extensively with buffer to remove unboundmaterials. The tomato
lectin bound to endothelial cells in wild-type and Gpihbp1–/–
mice; however, TRLs bound only to the capillaries of wild-type852 Cell Metabolism 19, 849–860, May 6, 2014 ª2014 Elsevier Inc.mice, and not to capillaries of Gpihbp1–/– mice (Figure S4A).
Occasional spots of ‘‘TRL binding’’ were detected in Gpihbp1–/–
hearts, but those were invariably explained by inadequate perfu-
sion with buffer (the same spots were positive for Alexa 647-
labeled rat IgG). The second line of evidence came from in vivo
TRL margination studies in Gpihbp1–/–Angptl4–/– mice (Sonnen-
burg et al., 2009), which have much lower plasma triglyceride
levels than Gpihbp1–/– mice (132 mg/dl in Gpihbp1–/–Angptl4–/–
mice versus 1,742 mg/dl in Gpihbp1–/– mice; n = 3/group). The
lower triglyceride levels are consistent with the marked increase
in chylomicron metabolism bymacrophages in the lymphatics of
Angptl4–/– mice (Lichtenstein et al., 2010). The margination of
IR-dye-labeled TRLs was absent in the heart capillaries of both
Gpihbp1–/–Angptl4–/– and Gpihbp1–/– mice (Figure S4B). As
expected, LPL was absent from the capillary lumen in both
Gpihbp1–/– and Gpihbp1–/–Angptl4–/– mice (Figure S4C).
The Binding of TRLs and Lipid Emulsions to Cultured
Cells Depends on GPIHBP1 and on the Lipid-Binding
Domain of LPL
The failure of TRLs to marginate within heart capillaries of
Gpihbp1–/– mice indicates the importance of GPIHBP1 in this
process. However, given GPIHBP1’s role in binding LPL and
shuttling it to the capillary lumen, it seemed possible that TRL
binding might also require GPIHBP1-bound LPL. Indeed, previ-
ous studies have suggested that GPIHBP1-expressing CHO
cells have little ability to bind TRLs in the absence of LPL (Gin
et al., 2011). This would also be consistent with the inhibition
of TRL margination in wild-type mice by heparin (Figure S3A).
Here, we pursued this possibility by examining TRL binding to
GPIHBP1-expressing CHL-11 cells, which produce only negli-
gible amounts of LPL (Gin et al., 2011). Again, we found no
TRL binding to those cells unless they were first preincubated
Figure 3. Dual-Axis Electron Microscopy Tomography of Hearts from Mice Injected with TRLs
Unlabeled TRLswere injected into a wild-typemouse. After 30 s, themousewas perfusedwith PBS to remove unbound lipoproteins. (A–C) TRLs on the surface of
capillary endothelial cells were in many cases attached to thinmembrane structures protruding from the luminal surface of endothelial cells, which we have called
nanovilli (NV). Nanovilli were also observed within intracellular vesicles (D–F) and at the basolateral plasma membrane (E). Scale bar, 70 nm. Nanovilli had the
‘‘railroad track’’ morphology of lipid bilayers (F). Immunogold EM studies to determine the subcellular localization of GPIHBP1. We foundmany instances of linear
arrays of gold particles extending into the capillary lumen or within intracellular vesicles (arrows) (G–I). Scale bar, 100 nm. For (A)–(F), see alsoMovie S4,Movie S5,
and Movie S6.
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bound LPL in TRL binding, we tested whether the LPL-specific
monoclonal antibody 5D2 would be capable of blocking TRL
binding. (Antibody 5D2 binds to residues 380–410 of human
LPL and blocks the delivery of long-chain triglyceride substrates
to LPL’s catalytic domain [Chang et al., 1998; Liu et al., 1992;
Lookene et al., 1997].) Interestingly, antibody 5D2 nearly abol-
ished binding of TRLs to GPIHBP1–LPL complexes on the sur-
face of CHL-11 cells, whereas a mouse monoclonal antibody
against the V5-tag had no effect (Figure 5A). To further assess
the role of GPIHBP1-bound LPL in capturing TRL particles, we
mutated a cluster of tryptophans in LPL (W390A/W393A/CW394A) that are known to be important for triglyceride hydrolysis
by LPL’s catalytic domain (and for the epitope of antibody 5D2)
(Lookene et al., 1997; Figure S5C). The mutant LPL bound avidly
to GPIHBP1, but the mutant LPL–GPIHBP1 complex could not
bind TRLs (Figure S5A). Mutating single tryptophan residues
yielded an intermediate phenotype (Figure S5A). These studies
implied that GPIHBP1-bound LPL binds TRLs and that the
same LPL sequences that are important for delivering triglyce-
ride substrates to LPL’s catalytic domain are responsible for
binding TRL particles on the surface of cells.
We also examined the ability of GPIHBP1–LPL complexes
on cells to bind triglyceride emulsion particles (Intralipid).ell Metabolism 19, 849–860, May 6, 2014 ª2014 Elsevier Inc. 853
Figure 4. The Binding of TRLs in the Heart Is Dependent on GPIHBP1 Expression
IR800-dye-labeled TRLs (green) and IR680-dye-labeled b-VLDL (red) were mixed together and injected into aGpihbp1+/+ and aGpihbp1–/– mouse. After 30 s, the
mice were perfused with PBS to remove unbound lipoproteins, followed immediately by fixative. Tissue sections (10 mm thick) were scanned on an Odyssey IR
imager, and the amounts of TRL and b-VLDL binding were measured and normalized to tissue area. (A) Images of tissue sections from the heart, brain, liver, and
brown adipose tissue (BAT) showing TRL binding in the heart in Gpihbp1+/+ mice, but not in Gpihbp1–/– mice. (C) Images of the same tissue sections showing
b-VLDL (red) binding, which was mainly in the liver. Quantification of TRL and b-VLDL binding is shown in (B) and (D), respectively. *p < 0.01 (Gpihbp1+/+ versus
Gpihbp1–/–).
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fected or GPIHBP1-transfected CHL-11 cells but did bind to
GPIHBP1-expressing cells that had been preincubated with
LPL (Figure 5B). The binding of Intralipid to cells could be
blocked with antibody 5D2 (Figure 5B) or by blocking LPL bind-
ing to GPIHBP1 with heparin (Figure S5B).
TRLs Bind to a GPIHBP1–LPL Complex In Vivo
The cell culture studies indicated that GPIHBP1 has little ability
to bind TRLs in the absence of LPL. To assess the in vivo rele-854 Cell Metabolism 19, 849–860, May 6, 2014 ª2014 Elsevier Inc.vance of these findings, we pursued two experimental
approaches. The first was to investigate the ability of TRLs to
stop in lung capillaries. Unlike heart and BAT, which express
high levels of both LPL and GPIHBP1, the lung expresses high
levels of GPIHBP1 but almost no LPL (Olafsen et al., 2010).
IR-dye-labeled TRLs did not marginate along lung capillaries in
wild-type mice (Figure S6). However, the lungs are able to
capture LPL from the circulation (Garcia-Arcos et al., 2013; Olaf-
sen et al., 2010), and after an intravenous injection of purified
bovine LPL, LPL levels increased in the lung (Figure S7A) and
Figure 5. ImmunofluoresenceMicroscopy Showing that the Binding of TRLs and Lipid Emulsions to Cells Depends on the Carboxyl-Terminal
Lipid-Binding Domain of LPL
CHL-11 cells were transfected with empty vector or S protein-tagged GPIHBP1. The cells were incubated with V5-tagged human LPL (h-LPL) in the absence or
presence of antibody 5D2, a mouse monoclonal antibody that blocks the lipid-binding domain of LPL (Chang et al., 1998), or a mouse monoclonal antibody
against the V5-protein tag. After washing the cells, the cells were incubated with (A) DiI-labeled TRLs (red) or (B) DiI-labeled Intralipid at 4C and the binding
determined by fluorescence microscopy. GPIHBP1 expression (green) and LPL binding (magenta) were determined with specific antibodies. Nuclei were stained
with DAPI (blue). Images were recorded on an Axiovert 200M microscope with a 203 objective.
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TRL Margination Depends on an LPL–GPIHBP1 Complexbound TRLs avidly (Figure 6A). In contrast, when bovine LPLwas
injected into Gpihbp1–/– mice, there was only a small increase in
TRL binding in the lungs (Figure 6A).
The second approach to investigate the importance of
GPIHBP1-bound LPL for TRL binding was to assess TRL
margination in the hearts of ‘‘L0-MCK’’ mice (homozygous Lpl
knockout mice that carry a human LPL transgene driven by the
muscle creatine kinase [MCK] promoter). These mice express
small amounts of human LPL in the heart (Levak-Frank et al.,
1997), which are transported to the capillary lumen by GPIHBP1.
The binding of IR-dye-labeled TRLs to hearts of L0-MCK mice
was greater than in Gpihbp1–/– mice but less than in wild-type
mice (Figure 6B). An intravenous injection of antibody 5D2 (which
binds to human LPL) lowered TRL binding in hearts of L0-MCK
mice to levels observed in Gpihbp1–/– mice. Antibody 5D2
does not bind to mouse LPL and did not inhibit TRL binding to
hearts of wild-type mice (Figure S7B).
Measurement of HSPG’s Role in TRLMargination In Vivo
Our studies showed that GPIHBP1-bound LPL has a major role
in TRL margination, but based on the residual binding of TRLs
in Gpihbp1–/– mouse tissues it seemed possible that endothelial
cell HSPGs might play a role. LPL contains positively charged
heparin-binding domains that are known to bind to negativelyCcharged sulfates on HSPGs. We tested the role of HSPG-bound
LPL in TRL margination in two ways. First, we quantified the
margination of TRLs in mice that lack NDST1 (N-deacetylase/
N-sulfotransferase1) in endothelial cells (Ndst1fl/flTek-Cre)
(Wang et al., 2005). NDST1 adds sulfates to HSPGs, and when
this enzyme is absent, HSPG sulfation is reduced by 50%
(Grobe et al., 2002). When IR-dye-labeled TRLs were injected
into Ndst1fl/flTek-Cre mice, the binding of the TRLs to the heart
was not reduced and actually appeared to be increased. In
the same hearts, the binding of IR-dye-labeled acetyl-LDL
(a chemically modified LDL that binds to endothelial cells) was
unaffected by a deficiency of NDST1 (Figure S7C).
In a second approach, we measured TRL margination in
mice that express human LPL in endothelial cells (EC-hLPLH
transgenic mice; Takahashi et al., 2008). LPL is normally pro-
duced by myocytes in the heart and requires GPIHBP1 to
move it across endothelial cells to the capillary lumen. How-
ever, in EC-hLPLH mice, catalytically active LPL would likely
be secreted directly into the circulation and have the opportu-
nity to bind to endothelial cell HSPGs. If some of this LPL
attaches to HSPGs, and if the HSPG–LPL complex is involved
in TRL margination, then TRL margination should be higher in
Gpihbp1–/–EC-hLpLH mice than in Gpihbp1–/– mice. However,
TRL margination in the heart was unaffected; the binding ofell Metabolism 19, 849–860, May 6, 2014 ª2014 Elsevier Inc. 855
Figure 6. Binding of TRLs in the Lung and Heart Is Dependent on
Both GPIHBP1 and LPL
(A) Wild-type and Gpihbp1 knockout mice were injected intravenously with
bovine LPL (65 mg in saline) or saline alone, followed by IR800-dye-labeled
TRLs (green). After 30 s, the mice were perfused with PBS to remove unbound
lipoproteins and the amount of TRL binding determined by IR scanning. In
saline-injected animals, TRL binding (green) was detected in the heart of the
wild-typemouse but very little in theGpihbp1–/–mouse. TRL binding in the lung
was negligible for both the wild-type mouse and the Gpihbp1–/– mouse. After
the injection of bLPL (+bLPL), there was a substantial increase in TRL binding
in the lung of wild-type mice, but not in the Gpihbp1–/– mouse. The results
normalized to tissue area are shown in the bar graph. *p < 0.01 (saline
versus +bLPL).
(B) IR800-dye-labeled TRLs (green) were injected into wild-type (WT),
Gpihbp1–/– (GpiKO), or Lpl–/– mice expressing a human LPL transgene in
muscle (‘‘L0-MCK’’). In another group of L0-MCKmice, amonoclonal antibody
against human LPL (5D2) was injected 3 min before the injection of TRLs. After
30 s, the amount of TRL binding wasmeasured as described in (A) (with theWT
set at a value of 1). Representative images of heart tissue sections are shown in
the insets. The anti-human LPL antibody reduced TRL binding in the hearts of
L0-MCK mice to levels observed in Gpihbp1–/– mice. The same antibody had
no effect on TRL binding in wild-type mice (Figure S7B). *p < 0.01 (versus
control).
Figure 7. LPL Produced Directly by Endothelial Cells Is Unable to In-
crease the Binding of TRLs in Gpihbp1 Knockout Mice
Wild-type (WT), Gpihbp1–/–, and Gpihbp1–/– mice expressing human LPL from
an endothelial cell-specific LPL transgene (Gpihbp1–/–EC-hLPL) were injected
with IR800-dye-labeled TRLs and IR680-dye-labeled lectin. After 30 s, the
mice were perfused with PBS to remove unbound materials, and the amounts
of TRL and lectin binding were measured by IR scanning. The expression of
human LPL in endothelial cells increased preheparin plasma LPL levels more
than 8-fold and reduced plasma triglyceride levels by more than 90% (for A,
triglycerides were 3,192 mg/dl versus 301 mg/dl; for B, triglycerides were
3,968 mg/dl versus 231 mg/dl). Quantitative analyses showed that LPL syn-
thesized and secreted by endothelial cells did not increase TRL binding in the
heart. Representative images of heart tissue sections from wild-type (WT),
Gpihbp1–/– (KO), and Gpihbp1–/–EC-hLPL (KOT) mice are shown in the insets.
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TRL Margination Depends on an LPL–GPIHBP1 ComplexTRLs to heart capillaries of Gpihbp1–/–EC-hLpLH mice was no
greater than in Gpihbp1–/– mice (Figure 7). To verify that some
of the EC-derived hLPL was intravascular, plasma hLPL levels
were measured after an injection of heparin. To circumvent
potential problems relating to the release of mouse LPL by856 Cell Metabolism 19, 849–860, May 6, 2014 ª2014 Elsevier Inc.heparin, we measured hLPL levels in mice that lacked mouse
LPL (i.e., Gpihbp1–/–EC-hLpLHLpl–/– and EC-hLpLHLpl–/–
mice). Plasma samples were obtained 5 min after heparin
because LPL appearance at that time point reflects release
from intravascular sites (Weinstein et al., 2008). As expected,
preheparin hLPL levels were low in both Gpihbp1–/–EC-
hLpLHLpl–/– and EC-hLpLHLpl–/– mice (0.13 ± 0.004 mg/ml
[n = 4] and 0.13 ± 0.05 mg/ml [n = 5], respectively). The
postheparin LPL levels were markedly increased in both
groups of mice: 19.88 ± 2.18 mg/ml (n = 4) in EC-hLpLHLpl–/–
mice and 3.61 ± 0.80 mg/ml (n = 5) in Gpihbp1–/–EC-
hLpLHLpl–/– mice.
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In the current studies, we show that GPIHBP1 is crucial for TRL
margination in the heart. Two observations support this conclu-
sion. First, in wild-type mice, the ability of endothelial cells to
bind fluorescently labeled TRLs correlates with GPIHBP1
expression. TRL binding was robust in capillaries, where
GPIHBP1 is expressed at high levels, but virtually undetectable
in larger blood vessels, where GPIHBP1 is absent. Second,
TRL margination is negligible in capillaries of Gpihbp1–/– mice,
as judged by immunofluorescence microscopy, transmission
EM, and laser-scanning quantification of IRdye-labeled TRL
binding in tissues. The failure of TRLs to bind to capillaries of
Gpihbp1–/– mice was not due to high plasma triglyceride levels,
because we observed the same results in experiments with iso-
lated, perfused hearts. Also, TRLs failed to marginate in heart
capillaries of Gpihbp1–/–Angptl4–/– mice and Gpihbp1–/–EC-
hLpLH mice, where plasma triglyceride levels are far lower.
Studies in cultured cells and live mice demonstrated the impor-
tance of GPIHBP1-bound LPL for TRL margination. In cultured
cells, neither TRLs nor Intralipid particles bound to GPIHBP1-
expressing cells unless the cells were first preincubated with
LPL. Also, the binding of TRLs and Intralipid to GPIHBP1–LPL
complexes on the surface of cells could be blocked with
the LPL-specific monoclonal antibody 5D2—or by releasing
LPL from GPIHBP1 with heparin. In live mice, heparin lowered
TRL margination to the low levels observed in Gpihbp1–/– mice.
Also, TRLs did not bind to GPIHBP1-rich capillaries of the
lung, a tissue that does not express LPL, unless the mice
were first injected with LPL. Finally, the margination of TRLs in
hearts of L0-MCK mice could be blocked with monoclonal
antibody 5D2.
It has often been proposed that TRL margination depends on
interactions between positively charged regions in TRL apoli-
poproteins with negatively charged HSPGs (Cryer, 1989; Gold-
berg, 1996). This model seems plausible, given that several
apolipoproteins on the surface of TRLs (e.g., apo-B, apo-AV,
apo-E) have heparin-binding domains and bind to negatively
charged HSPGs (Brown and Goldstein, 1986; Cardin et al.,
1984, 1986; Lookene et al., 2005). In a variation on this model,
HSPG-bound LPL plays a role in TRL binding. However, we
were unable to document a major role for HSPGs in TRL
margination in the heart. TRL margination in heart capillaries
of endothelial cell-specific Ndst1 knockout mice was not
reduced. Consistent with this finding, inactivation of Ndst1 in
endothelial cells did not affect the amount of LPL that enters
the plasma after an injection of heparin (Weinstein et al.,
2008). Moreover, an endothelial cell-specific LPL transgene
was unable to increase the low TRL margination in Gpihbp1
knockout mice. In these mice, substantial amounts of human
LPL could be released into the bloodstream with an injection
of heparin (3.6 mg hLPL/ml plasma). Presumably, this LPL
was bound to HSPGs on the luminal surface of blood vessels.
If an LPL–HSPG complex was highly effective in mediating TRL
binding, one might have expected higher TRL binding in Gpihb-
p1–/–EC-hLpLH mice than in Gpihbp1–/– mice. However,
this was not the case, underscoring the importance of
endothelial cell GPIHBP1 in LPL binding and TRL margination
in the heart.CA recent study by Bartelt et al. (2011) showed that an injection
of heparin into wild-type mice blocked the margination of triglyc-
eride-rich particles along capillaries of BAT. Their studies did not
address whether the inhibition of margination was due to hepa-
rin’s ability to block interactions between HSPGs and the parti-
cles or to heparin’s ability to release LPL from the surface of cap-
illaries. The current studies show that the inhibition is mainly due
to the heparin-mediated release of LPL from GPIHBP1.
LPL is enzymatically active only as a head-to-tail homodimer
(Wong et al., 1997), and it appears likely that a tryptophan-rich
motif within the carboxyl terminus of one monomer delivers
triglyceride substrates to the amino-terminal catalytic domain
of the partner monomer. In support of this idea, transfection of
two catalytically inactive LPLs—one with a mutation in the
carboxyl-terminal lipid-binding motif and the other with a muta-
tion in the amino-terminal catalytic domain—yields catalytically
active LPL (Kobayashi et al., 2002). Mutating LPL’s carboxyl-
terminal tryptophan-rich cluster or incubating LPL with antibody
5D2 (which binds to this region of the molecule) blocks the
hydrolysis of triolein (Liu et al., 1992; Lookene et al., 1997). Our
current studies showed that the same interventions block TRL
binding to GPIHBP1–LPL complexes, both on cultured cells
and in capillaries of live mice. Thus, we identified an unexpected
simplicity in LPL action: the same carboxyl-terminal LPL
sequences required for catalysis are critical for the margination
of TRL particles in capillaries.
An intriguing finding in the current studies was the discovery,
by dual-axis EM tomography, of 6 nm-thick planes of lipid
bilayer, which we have called nanovilli, that extend from the sur-
face of endothelial cells into the capillary lumen. The samemem-
brane bilayer structures are found in transcytotic vesicles and on
the basolateral face of endothelial cells. The membrane bilayer
structures appear as ‘‘sticks’’ on single EM micrographs; how-
ever, when tomographic images are assembled into a movie,
the overall structure is evident—they are not sticks but lipid
bilayer ‘‘planes’’ (6 nm thick, 30–40 nm long, and 100–
200 nm tall). As far as we are aware, these membrane bilayers
have not been described previously, likely because most ultra-
structural studies of heart capillary endothelial cells have been
conducted with routine transmission EM. While these structures
can be identified by transmission EM, they are not as clear, and
they are easier to overlook and/or dismiss. It seems likely that
these structures contain GPIHBP1 and LPL because they were
found in close association with TRLs and because we often
detected, by immunogold EM, linear ‘‘strings’’ of gold particles
extending into the capillary lumen and in intracellular vesicles
(the same sites where nanovilli are observed by dual-axis tomog-
raphy). In the immunogold EM studies, silver enhancement of the
1.4 nm gold beads interfered with osmium tetroxide/uranyl
acetate staining of membranes, making it difficult to visualize
lipid bilayers underlying the strings of gold particles. Earlier EM
studies described endothelial cell ‘‘projections’’ that bulged
into the capillary lumen, especially near endothelial cell junctions
(Blanchette-Mackie et al., 1989; Moore and Ruska, 1957).
However, those projections contain abundant cytoplasm and
are quite distinct from the membrane bilayer structures that we
have described.
In summary, we have used biochemical, imaging, and EM
approaches to study the mechanisms of TRL margination inell Metabolism 19, 849–860, May 6, 2014 ª2014 Elsevier Inc. 857
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TRL Margination Depends on an LPL–GPIHBP1 Complexcultured cells and in new mouse models. We have also devel-
oped quantitative methods to assess TRL margination in live
animals. Our studies show that TRL margination depends on
GPIHBP1-bound LPL and specifically on sequences within the
carboxyl terminus of LPL. HSPGs do not appear to have a large
quantitative role in margination. The studies also identified an
endothelial cell structure that we have called nanovilli. Given
the association of nanovilli with TRLs, we speculate that these
structures play a role capturing TRL particles along capillaries.
EXPERIMENTAL PROCEDURES
Measurement of Lipoprotein Binding in Tissues
Mice were injected intravenously with 50 ml of 5 mM THL. After 2 min, the mice
were injected intravenously with 50–100 mg IR-dye-labeled lipoproteins (see
Supplemental Information). After 30 s, the mice were perfused with 15 ml ice-
cold PBS to remove unbound lipoproteins, followed immediately by 10 ml
ice-cold 3% PFA in PBS. Tissue samples were frozen in O.C.T., and 10 mm-
thick sections were placed onto glass slides and scanned with an Odyssey
IR imager. The IR signal for each channel was measured and normalized to
tissue area. Tissue area was determined with ImageJ software. The results
are reported as themean ± SD. Each experimentwas done at least three times,
and only representative experiments are shown, except where indicated.
Lipoprotein Binding in Isolated Perfused Hearts
Anesthetized mice were injected intravenously with 50 ml of 5 mM THL. After
2 min, the mice were perfused with 10 ml of Tyrode’s solution (136 mM NaCl,
5.4 mM KCl, 0.33 mM NaH2PO4, 1 mM MgCl2, 10 mM HEPES [pH 7.4],
10 mM glucose) through the inferior vena cava. The hearts were removed
and the aorta cannulated with a blunt-end 20-gauge needle and secured
with a suture. The hearts were flushed with Tyrode’s solution, submerged
in 30 ml Tyrode’s solution, and perfused with a 1 ml solution containing
100 mg/ml Alexa 555-labeled TRLs, 50 mg/ml FITC-labeled lectin, and
25 mg/ml Alexa 647-labeled rat IgG. After 5 min, the hearts were perfused
with 10 ml Tyrode’s solution followed by 5 ml of 3% PFA in PBS. The hearts
were frozen in O.C.T. and processed for fluorescence microscopy (see
Supplemental Information).
Detection of TRL Binding in the Heart by Transmission Electron
Microscopy and Dual-Axis Electron Tomography
Mice were injected with THL and TRLs (50–100 mg) as described for the IR-
dye-labeled lipoproteins. After 30 s, tissues were perfusion fixed in situ with
2.5% glutaraldehyde containing 2 mM MgCl2 in 100 mM cacodylate buffer
(pH 7.4) and incubated in the fixation solution at 4C overnight. The following
day, the tissues were incubated in an equal volume of 1% osmium tetroxide
and 0.1 M imidazole (pH 7.5). The samples were then washed three times in
distilled water (10 min each). Samples were then treated with 1% osmium
tetroxide in 100 mM cacodylate buffer for 1 hr, washed in distilled water four
times (10 min each), and then treated with 1%–2% aqueous uranyl acetate
overnight at 4C in the dark. The samples were sequentially dehydrated with
increasing concentrations of acetone (20%, 30%, 50%, 70%, 90%, and
100%) for 30 min each, followed by three additional treatments with 100%
acetone for 20 min each. Samples were then infiltrated with increasing con-
centrations of epon or Spurr’s resin (25% for 1 hr, 50% for 1 hr, 75% for
1 hr, 100% for 1 hr, 100% overnight at room temperature) and then incubated
overnight at 70C in a resin mold. Sections 50–90 nm thick were cut with
a Leica ultramicrotome.
For routine transmission EM, samples were examined with a 100CX JEOL
electron microscope. For EM tomography, 250 nm-thick sections were
collected on formvar-coated copper slot grids. Following staining, 15 nm
colloidal gold particles were applied to both surfaces of the grid to serve as
fiducial markers for subsequent image analysis. Dual-axis tilt series (–65
to +65 at 1 intervals) were obtained with a computerized tilt stage with an
FEI Tecnai TF30 and Tecnai TF20 electron microscopes operating at 300 kV
and 200 kV, respectively. Tomographic reconstruction and modeling was per-
formed with the IMOD software package (Mastronarde, 1997).858 Cell Metabolism 19, 849–860, May 6, 2014 ª2014 Elsevier Inc.Detection of TRL Margination by High-Resolution Secondary Ion
Mass Spectrometry
Endogenously labeled 13C-TRLs were harvested from Gpihbp1–/– mice after
delivering amixture of 13C-labeled Algal fatty acids (Sigma 487937) by gavage.
TRLs were isolated by ultracentrifugation, and 50 mg was injected into mice.
After 8 min, the mice were perfused with PBS to remove unbound lipoproteins,
followed by glutaraldehyde fixative. Tissue samples were processed as
described for transmission EM except that 500 nm-thick sections were cut
and placed onto platinum-coated coverslips.
ACAMECANanoSIMS50wasused toacquire chemical and isotopic images.
The instrument uses a 16 keVprimaryCs+ ionbeam tobombard the sample sur-
face, and five selected secondary ions were detected to form composition
maps with 50 nm spatial resolution. The ratio between the counts of 12C-
and 13C-secondary ionswas used to show the distribution of 13C-labeled lipids;
the 16O-signals, 12C14N-signals, and 31P-signals were also collected to show
the morphology of the samples. The smallest primary aperture (D1 = 4) was
used to achieve high spatial resolution images of capillaries (10 3 10 mm,
256 3 256 pixels). The 13C/12C-hue saturation images (HSI) were processed
by the OpenMIMS plug-in (MIMS, Harvard University; http://www.nrims.
harvard.edu) in ImageJ software and processed by a median filter with three-
pixel radius. All sections analyzed by NanoSIMS were also studied by low
voltage Back Scattered Electron (BSE) imaging at 2 kV in a Zeiss NVision FIB
to allowdirect correlationof the chemical informationwith the sample structure.
Detection of GPIHBP1 by Transmission Electron Microscopy
Isolated mouse hearts were perfused with 1.0 ml Tyrode’s buffer containing
50 mg/ml of a rat anti-GPIHBP1 antibody (clone 11A12). After incubating for
5min at RT, unbound antibodywas removed by perfusingwith 5ml of Tyrode’s
buffer. Bound antibody was detected by incubation with 36 mg/ml Alexa 488-
labeled goat anti-rat Fab0 fragments coupled to 1.4 nm gold particles (Nanop-
robes, Yaphank, NY). The heart was perfusion fixed with glutaraldehyde and
incubated in the fixative at 4C. Small pieces of tissue (1 mm cubes) were
treated with an HQ Silver Enhancement Kit (Nanoprobes) according to the
manufacturer’s instructions and then processed for EM as described earlier.
Binding of TRLs to Gpihbp1-Transfected Cells
CHL-11 cells were plated on coverslips in 24-well plates and transfected with
either 0.8 mg of an S protein-taggedGpihbp1 expression vector or empty vector
using Lipofectamine 2000 (Invitrogen). After 24 hr, the cells were washed with
binding buffer (PBS containing 1.0 mM CaCl2, 1.0 mM MgCl2, and 0.5% BSA)
and incubated at 4C for 1 hr with 400 ml of concentrated conditioned medium
from cells expressing V5-tagged human LPL. LPL mutants were generated by
site-directed mutagenesis with the QuikChange Lightning Kit (Agilent). All con-
structswere validatedbyDNAsequencing. Somecellswere also incubatedwith
mouse monoclonal antibody 5D2 (10 mg/ml) or a mouse monoclonal antibody
against the V5 tag (10 mg/ml, Invitrogen) at 4C for 1 hr. Cells were then washed
three times with binding buffer and incubated with 0.5 ml DiI-labeled TRLs
(1mg/ml) in binding buffer at 4C for 2 hr (Gin et al., 2011). The cellswerewashed
to remove unbound TRLs, fixed with 3% PFA, blocked, and incubated with a
rabbit polyclonal antibody against the S protein tag (0.4 mg/ml) and a mouse
monoclonal antibody against V5 (4 mg/ml). After washing, the cells were incu-
bated with Alexa 488-labeled donkey anti-rabbit IgG (1:500) and an Alexa
647-labeled donkey anti-mouse IgG (1:500). After the removal of unbound sec-
ondary antibodies, the cells were stained with DAPI to visualize nuclei. Images
were captured on an Axiovert 200M microscope (equipped with an LSM 700
confocal scanning module) and processed with the Zen 2010 software. The
exposure conditions for each experimental condition were fixed and identical.
Statistical Analysis
Statistical analyses were performed with GraphPad QuickCalcs (http://www.
graphpad.com/). Differences in levels of TRL margination were analyzed by
a two-tailed Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, six movies, and Supple-
mental Experimental Procedures and can be found with this article at http://
dx.doi.org/10.1016/j.cmet.2014.01.017.
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